AAVANTIBIO
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
AAVANTIBIO
Social Links:
Industry:
Biotechnology Genetics Health Care Life Science
Founded:
2020-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.aavantibio.com
Total Employee:
11+
Status:
Active
Total Funding:
107 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager WordPress Sitelinks Search Box Organization Schema
Similar Organizations
hC Bioscience
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA.
Hive
Hive Biosystems helps pharmaceutical companies streamline genetics-driven drug discovery by rapidly generating transgenic animals.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
RA Capital Management
RA Capital Management investment in Series A - AavantiBio
Sarepta Therapeutics
Sarepta Therapeutics investment in Series A - AavantiBio
Bain Capital Life Sciences
Bain Capital Life Sciences investment in Series A - AavantiBio
SV Health Investors
SV Health Investors investment in Series A - AavantiBio
Perceptive Advisors
Perceptive Advisors investment in Series A - AavantiBio
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-16 | AavantiBio Further Enhances Leadership Team with Appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer |
| 2021-03-30 | Aavantibio taps Wright as chief medical officer |
Official Site Inspections
http://www.aavantibio.com Semrush global rank: 1.95 M Semrush visits lastest month: 11.04 K
Unable to get host informations!!!
More informations about "AavantiBio"
AavantiBio, Inc. - LinkedIn
AavantiBio, Inc. | 4,058 followers on LinkedIn. Advancing Gene Therapy | AavantiBio is a gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors ...See details»
Solid Biosciences Announces Acquisition of AavantiBio …
Sep 30, 2022 CHARLESTOWN, Mass. and CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne ...See details»
AavantiBio Company Profile 2024: Valuation, Investors …
AavantiBio General Information Description. Developer of a gene therapy designed to transform the lives of patients with rare genetic diseases. The company offers treatment and research for a rare inherited disorder that …See details»
Solid Biosciences Announces Acquisition of AavantiBio and
Sep 30, 2022 AavantiBio is currently developing AVB-401, a preclinical-stage product candidate, for the treatment of BAG3. ... About the Proposed Transactions, Management and …See details»
Gene Therapy Company AavantiBio Launches with $107 Million
Oct 22, 2020 AavantiBio will pursue a diversified gene therapy pipeline, ... “Bo Cumbo has built a first-in-class rare disease commercial organization and has made tremendous contributions …See details»
Solid Biosciences Announces Closing of Acquisition of
May 12, 2022 Bo Cumbo, the Chief Executive Officer of AavantiBio, will assume the role of President and CEO of Solid Biosciences. Concurrent with the closing of the merger, Solid …See details»
AavantiBio Company Profile - Office Locations, Competitors ... - Craft
AavantiBio is a biotechnology company dedicated to gene therapy research in the rare disease space. The company focuses on hereditary genetic illnesses, such as Ataxia Friedreich …See details»
AavantiBio Launches with $107 Million Financing for Rare Disease …
Oct 22, 2020 AavantiBio’s lead program builds on the foundational research efforts of Byrne and Corti in Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and …See details»
AavantiBio - Contacts, Employees, Board Members, Advisors
AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.See details»
AavantiBio Announces Formation of Scientific Advisory Board
Feb 9, 2022 About AavantiBio, Inc. AavantiBio is a gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, …See details»
Sarepta, continuing its gene therapy push, helps launch a startup
Oct 22, 2020 The disease affects approximately 1 in every 40,000 people, according to the National Organization for Rare Disorders, which would equate to around 8,200 patients in the …See details»
Sarepta helps bankroll new gene therapy startup AavantiBio
Nov 21, 2024 Sarepta chief commercial officer Bo Cumbo has left to head up gene therapy venture – AavantiBio – with $107 million in backing from his former employer and three high …See details»
Gene Therapy Company AavantiBio Launches with $107 Million …
Oct 22, 2020 AavantiBio will benefit from strategic partnerships with the University of Florida’s renowned Powell Gene Therapy Center and the MDA Care Center at UF Health where Drs. …See details»
AavantiBio Further Enhances Leadership Team with ... - Business Wire
Nov 16, 2021 About AavantiBio, Inc. AavantiBio is a gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, …See details»
Gene Therapy Company AavantiBio Launches with $107 Million
Oct 22, 2020 AavantiBio will pursue a diversified gene therapy pipeline, ... “Bo Cumbo has built a first-in-class rare disease commercial organization and has made tremendous contributions …See details»
Bain Capital, others invest $107M in new gene therapy company …
Oct 23, 2020 Newly formed gene therapy company AavantiBio Inc. raised $107 million in a series A funding round led by a life sciences-focused investor group including Bain Capital Life …See details»
AavantiBio Furthers Strategic Partnership with University of Florida …
Oct 12, 2021 AavantiBio, launched in October 2020 with foundational financial backing from some of the life science industry’s leading investors, has announced strategic partnerships …See details»
Gene Therapy Company AavantiBio Launches with $107 Million …
Oct 22, 2020 AavantiBio will pursue a diversified gene therapy pipeline, ... “Bo Cumbo has built a first-in-class rare disease commercial organization and has made tremendous contributions …See details»
AavantiBio and Resilience Announce Strategic Collaboration for …
Jun 3, 2021 AavantiBio is a gene therapy company backed by a premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences, and RA Capital …See details»